Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Colorectal Neoplasms 2Solid Tumors 1Sarcoma 1Pyloric Stenosis, Hypertrophic 1Gastrointestinal Neoplasms 1Carcinoma, Transitional Cell 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × brivanib × Clear all
NCT00355238 2023-12-01

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Bristol-Myers Squibb

Phase 2 Completed
137 enrolled 20 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00908752 2019-12-02

BRISK TA

Bristol-Myers Squibb

Phase 3 Completed
734 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01108705 2015-10-12

BRISK-APS

Bristol-Myers Squibb

Phase 3 Terminated
87 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01540461 2014-07-08

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Bristol-Myers Squibb

Phase 1 Completed
17 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00437424 2011-05-04

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡